Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials

Chest

Volumn 152, Issue 6, 2017, Pages 1159-1168

  Zhang, Wen ^a   Zhang, Yi ^a   Li, Chuan Wei ^b   Jones, Paul ^d   Wang, Chen ^a,c   Fan, Ye ^a  

^a Xinqiao Hospital   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

COPD; pooled analysis; pulmonary; statin drugs

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; HUMAN; INFLAMMATION; LUNG FUNCTION; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85038217929     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.08.015     Document Type: Article

References (41)

1. Vogelmeier, C.F., Criner, G.J., Martinez, F.J., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med 195:5 (2017), 557–582.
2. Oudijk, E.J., Lammers, J.W., Koenderman, L., Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 46 (2003), 5s–13s.
3. Young, R.P., Hopkins, R.J., Agusti, A., Statins as adjunct therapy in COPD: how do we cope after STATCOPE?. Thorax 69:10 (2014), 891–894.
4. Maneechotesuwan, K., Wongkajornsilp, A., Adcock, I.M., Barnes, P.J., Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest 148:5 (2015), 1164–1176.
5. Mroz, R.M., Lisowski, P., Tycinska, A., et al. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol 66:1 (2015), 111–128.
6. Young, R.P., Hopkins, R.J., Update on the potential role of statin drugs in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev Respir Med 7:5 (2013), 533–544.
7. Lee, J.H., Lee, D.S., Kim, E.K., et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172:8 (2005), 987–993.
8. Zeki, A.A., Franzi, L., Last, J., Kenyon, N.J., Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180:8 (2009), 731–740.
9. Ingebrigtsen, T.S., Marott, J.L., Nordestgaard, B.G., Lange, P., Hallas, J., Vestbo, J., Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 70:1 (2015), 33–40.
10. Raymakers, A.J.N., Sadatsafavi, M., Sin, D.D., De Vera, M.A., Lynd, L.D., The impact of statin use on all-cause mortality in patients with COPD: a population based cohort study. Chest 152:3 (2017), 486–493.
11. Criner, G.J., Connett, J.E., Aaron, S.D., et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370:23 (2014), 2201–2210.
12. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:4 (2009), 264–269.
13. Friedrich, J.O., Adhikari, N.K., Beyene, J., Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol, 7, 2007, 5.
14. Chogtu, B., Kuriachan, S., Magazine, R., et al. A prospective, randomized study: evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Indian J Pharmacol 48:5 (2016), 503–508.
15. Ghobadi, H., Lari, S.M., Pourfarzi, F., Mahmoudpour, A., Ghanei, M., The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: a randomized controlled trial. J Res Med Sci 19:2 (2014), 99–105.
16. John, M.E., Cockcroft, J.R., McKeever, T.M., et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 10 (2015), 211–221.
17. Lee, T.M., Lin, M.S., Chang, N.C., Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 101:4 (2008), 530–535.
18. Lee, T.M., Chen, C.C., Shen, H.N., Chang, N.C., Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 116:6 (2009), 497–505.
19. Moosavi, S.A., Raji, H., Faghankhani, M., Yazdani, R., Esmaeili, M., Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial. Iran Red Crescent Med J 15:8 (2013), 649–654.
20. Neukamm, A., Høiseth, A.D., Einvik, G., et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med 278:1 (2015), 59–67.
21. Kaczmarek, P., Sładek, K., Skucha, W., et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 120:1-2 (2010), 11–17.
22. Liu, H.F., Qi, X.W., Ma, L.L., Yao, D.K., Wang, L., Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease. Exp Clin Cardiol 18:1 (2013), e40–e43.
23. Undas, A., Kaczmarek, P., Sladek, K., et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 102:6 (2009), 1176–1182.
24. Maneechotesuwan, K., Kasetsinsombat, K., Wongkajornsilp, A., Barnes, P.J., Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in patients with COPD through an IL-13-dependent mechanism. Respir Res, 17(1), 2016, 104.
25. John, M., Knox, A., McKeever, T., et al. The effects of statin therapy on inflammatory markers in patients with COPD: a double blind randomised controlled trial. Thorax 68 (2013), A16–A17.
26. John, M., Cockcroft, J., McKeever, T., et al. Cardiovascular effects of statin therapy on arterial stiffness in patients with COPD: a double blind randomised controlled trial. Thorax, 68, 2013, A133.
27. Rossi, A., Inciardi, R.M., Rossi, A., et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther 44 (2017), 16–23.
28. Balaguer, C., Peralta, A., Ríos, Á., et al. Effects of simvastatin in chronic obstructive pulmonary disease: results of a pilot, randomized, placebo-controlled clinical trial. Contemp Clin Trials Commun 2 (2016), 91–96.
29. Morris, A., Fitzpatrick, M., Bertolet, M., et al. Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease. AIDS 31:4 (2017), 539–544.
30. Arian, A., Moghadam, S.G., Kazemi, T., Hajihosseini, M., The effects of statins on pulmonary artery pressure in patients with chronic obstructive pulmonary disease: a randomized controlled trial. J Res Pharm Pract 6:1 (2017), 27–30.
31. Marin, L., Colombo, P., Bebawy, M., Young, P.M., Traini, D., Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv 8:9 (2011), 1205–1220.
32. Mancini, G.B., Etminan, M., Zhang, B., Levesque, L.E., FitzGerald, J.M., Brophy, J.M., Reduction of morbidity and mortality by statin drugs, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47:12 (2006), 2554–2560.
33. Cao, C., Wu, Y., Xu, Z., et al. The effect of statin drugs on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research. Sci Rep, 5, 2015, 16461.
34. Janda, S., Park, K., FitzGerald, J.M., Etminan, M., Swiston, J., Statins in COPD: a systematic review. Chest 136:3 (2009), 734–743.
35. Vanfleteren, L.E., Spruit, M.A., Wouters, E.F., Franssen, F.M., Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med 4:11 (2016), 911–924.
36. Decramer, M., Janssens, W., Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 1:1 (2013), 73–83.
37. Hole, D.J., Watt, G.C., Davey-Smith, G., Hart, C.L., Gillis, C.R., Hawthorne, V.M., Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313:7059 (1996), 711–715.
38. Mannino, D.M., Thorn, D., Swensen, A., Holguin, F., Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32:4 (2008), 962–969.
39. Sin, D.D., Anthonisen, N.R., Soriano, J.B., Agusti, A.G., Mortality in COPD: role of comorbidities. Eur Respir J 28:6 (2006), 1245–1257.
40. Calverley, P.M., Anderson, J.A., Celli, B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:8 (2007), 775–789.
41. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.